RADIUS PHARMACEUTICALS INC has a total of 68 patent applications. It increased the IP activity by 57.0%. Its first patent ever was published in 2016. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are ANHUI HEAL STAR PHARMACEUTICAL CO LTD, HUAIAN PEIYUAN GENE TECH CO LTD and SMALL PHARMA LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 10 | |
#2 | WIPO (World Intellectual Property Organization) | 8 | |
#3 | Australia | 7 | |
#4 | Canada | 6 | |
#5 | Israel | 6 | |
#6 | Republic of Korea | 6 | |
#7 | EPO (European Patent Office) | 5 | |
#8 | Singapore | 5 | |
#9 | Brazil | 4 | |
#10 | Mexico | 4 | |
#11 | Hong Kong | 3 | |
#12 | China | 2 | |
#13 | Russian Federation | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Hattersley Gary | 27 |
#2 | Markey Michael | 15 |
#3 | Eberlin Alex | 14 |
#4 | Edwards Richard | 14 |
#5 | Sheth Pratik | 14 |
#6 | Bolger Joshua Kyle | 12 |
#7 | Mckenzie Jonathan Blake | 12 |
#8 | Garner Fiona | 9 |
#9 | Miller Chris | 9 |
#10 | Cruskie Michael Paul | 8 |
Publication | Filing date | Title |
---|---|---|
WO2021016254A1 | Estrogen receptor-modulating compounds | |
WO2020167855A1 | Processes and compounds | |
WO2020118202A1 | Methods for treating cancer in models harboring esr1 mutations | |
WO2020118213A1 | Methods for treating cancer resistant to cdk4/6 inhibitors | |
WO2020112765A1 | Elacestrant in combination with abemaciclib in women with breast cancer | |
AU2019297421A1 | Polymorphic forms of RAD 1901-2HCL | |
SG11202006942WA | Estrogen receptor-modulating compounds | |
AU2018205285A1 | Polymorphic forms of RAD1901-2HCl | |
AU2017336564A1 | Methods for treating ovarian cancer |